Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Prostatic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Multiple Myeloma 1Lung Neoplasms 1Ewing's Sarcoma Family of Tumors 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Breast Diseases 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

pembrolizumab 20Cisplatin 17Cetuximab 13Docetaxel 11Paclitaxel 9Carboplatin 9Radiotherapy 8Fluorouracil 6cemiplimab 5130-nm albumin-bound paclitaxel 5Bleomycin 4Radiation 3Pemetrexed 3Panitumumab 3Nivolumab 3Gemcitabine 3Albumin-Bound Paclitaxel 3vandetanib 2talimogene laherparepvec 2selinexor 2motexafin gadolinium 2figitumumab 2brigatinib 2avelumab 2atezolizumab 2alpha-2'-deoxythioguanosine 2advexin 2Taxes 2ON 01910 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Squamous Cell × figitumumab × Clear all
NCT00596830 2014-01-13

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Pfizer

Phase 3 Terminated
681 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell

NCT00673049 2013-07-24

NSCLC

Pfizer

Phase 3 Terminated
583 enrolled 11 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡